[News] Agreements to provide affordable lenacapavir

11th Mar, 2026

Microbe / Infectious Research

The Lancet

On Sept 24, 2025, two agreements were announced between funders and generic drug manufacturers. The two agreements ensured the availability of groundbreaking twice-yearly injectable HIV pre-exposure prophylaxis (PrEP) drug lenacapavir at an annual price of US$40 per patient in 120 low-income and middle-income countries (LMICs) from 2027.

Published By: The Lancet

Microbe / Infectious Research

11th Mar, 2026

The Lancet

[Personal View] Controlled human infection with Mycobacterium tuberculosis: practical considerations for clinical trials

Microbe / Infectious Research

11th Mar, 2026

The Lancet

[Personal View] (Un)intended consequences: a social sciences stocktake of a decade of Global Action Plan-inspired antimicrobial governance

Microbe / Infectious Research

11th Mar, 2026

The Lancet

[Personal View] An overview of global public and philanthropic investments into antibacterial therapeutics (2017–23)

Microbe / Infectious Research

11th Mar, 2026

The Lancet

[Articles] Serotype-specific pneumococcal invasiveness: a global meta-analysis of paired estimates of disease incidence and carriage prevalence

Microbe / Infectious Research

11th Mar, 2026

The Lancet

[Articles] Bedaquiline resistance in patients with Xpert MTB/RIF Ultra-tested rifampicin-resistant tuberculosis in the Western Cape, South Africa: a prospective study

Microbe / Infectious Research

11th Mar, 2026

The Lancet

[Articles] Characterisation of Bordetella pertussis virulence and macrolide resistance in Australia by targeted culture-independent sequencing: a genomic epidemiology study

Microbe / Infectious Research

11th Mar, 2026

The Lancet

[News] Agreements to provide affordable lenacapavir

Related Articles

[Personal View] Controlled human infection with Mycobacterium tuberculosis: practical considerations for clinical trials

[Personal View] (Un)intended consequences: a social sciences stocktake of a decade of Global Action Plan-inspired antimicrobial governance

[Personal View] An overview of global public and philanthropic investments into antibacterial therapeutics (2017–23)

[Articles] Serotype-specific pneumococcal invasiveness: a global meta-analysis of paired estimates of disease incidence and carriage prevalence

[Articles] Bedaquiline resistance in patients with Xpert MTB/RIF Ultra-tested rifampicin-resistant tuberculosis in the Western Cape, South Africa: a prospective study

[Articles] Characterisation of Bordetella pertussis virulence and macrolide resistance in Australia by targeted culture-independent sequencing: a genomic epidemiology study

[Articles] Spatiotemporal patterns of Rift Valley fever virus in Africa: a retrospective genomic epidemiology and phylodynamic modelling study

[News] Agreements to provide affordable lenacapavir

Related Articles

[Personal View] Controlled human infection with Mycobacterium tuberculosis: practical considerations for clinical trials

[Personal View] (Un)intended consequences: a social sciences stocktake of a decade of Global Action Plan-inspired antimicrobial governance

[Personal View] An overview of global public and philanthropic investments into antibacterial therapeutics (2017–23)

[Articles] Serotype-specific pneumococcal invasiveness: a global meta-analysis of paired estimates of disease incidence and carriage prevalence

[Articles] Bedaquiline resistance in patients with Xpert MTB/RIF Ultra-tested rifampicin-resistant tuberculosis in the Western Cape, South Africa: a prospective study

[Articles] Characterisation of Bordetella pertussis virulence and macrolide resistance in Australia by targeted culture-independent sequencing: a genomic epidemiology study

[Articles] Spatiotemporal patterns of Rift Valley fever virus in Africa: a retrospective genomic epidemiology and phylodynamic modelling study